Yao-Chang Xu, Abbisko CEO

Shang­hai's Ab­bisko out-li­cens­es EGFR can­di­date in po­ten­tial­ly nine-fig­ure deal

A Shang­hai-based biotech is hand­ing off rights to one of its can­di­dates to an­oth­er Shang­hai com­pa­ny.

Qim­ing-backed Ab­bisko — head­ed by Eli Lil­ly and No­var­tis vet­er­an Yao-Chang Xu — said Wednes­day that it would be out-li­cens­ing its can­di­date ABK3376 to Al­list Phar­ma­ceu­ti­cals. The small mol­e­cule is a pre­clin­i­cal, brain-pen­e­trant EGFR in­hibitor which can in­hib­it dif­fer­ent mu­ta­tions such as L858R ac­ti­vat­ing mu­ta­tion or the ex­on 19 dele­tion mu­ta­tion, Ab­bisko said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.